Japanese pharma group Otsuka has agreed to acquire Transcend Therapeutics and its MDMA-based drug candidate for post-traumatic stress disorder (PTSD) and other psychiatric conditions for $700 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results